GSK planning BLA for dostarlimab in endometrial cancer

GSK plans to submit a BLA to FDA at the end of the year for dostarlimab (formerly

Read the full 179 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE